AstraZeneca Pharma India Limited and Dr. Reddy’s Laboratories Ltd. Collaborate to marketing for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed dose combination with metformin respectively, promoted and marketed in the Indian market.
Sun Pharmaceutical Industries and AstraZeneca Pharma India (AZPIL) have entered agreement for distribution of AstraZeneca’s brand “Axcer”, a new brand of ticagrelor in India. This drug is used for the treatment of acute coronary syndrome (ACS). AZPIL already has a brand under the trademark “Brilinta”, for ticagrelor molecule, launched and marketed by AZPIL in India since 2012. This collaboration will provide customers access to this latest generation treatment option for ACS.
AstraZeneca, innovation-driven biopharmaceutical business, to invest approximately $285 million in a new facility for manufacturing of biological medicines in Södertälje, Sweden. Södertälje is currently main Place to AstraZeneca’s largest global tablets and capsules manufacturing facility. Company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden operations unit.
The new plant will be focused on filling and packaging of protein therapeutics.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
